Research Analysts’ Weekly Ratings Changes for Day One Biopharmaceuticals (DAWN)

A number of research firms have changed their ratings and price targets for Day One Biopharmaceuticals (NASDAQ: DAWN):

• 3/11/2026 – Day One Biopharmaceuticals had its “neutral” rating reaffirmed by JPMorgan Chase & Co.. They now have a $21.50 price target on the stock, down from $27.00.
• 3/10/2026 – Day One Biopharmaceuticals had its “neutral” rating reaffirmed by HC Wainwright. They now have a $21.50 price target on the stock, down from $22.00.
• 3/9/2026 – Day One Biopharmaceuticals had its “neutral” rating reaffirmed by Wedbush. They now have a $21.50 price target on the stock, down from $30.00.
• 3/6/2026 – Day One Biopharmaceuticals was downgraded by TD Cowen from “buy” to “hold”.
• 3/6/2026 – Day One Biopharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 3/6/2026 – Day One Biopharmaceuticals was downgraded by Wedbush from “strong-buy” to “hold”.
• 3/6/2026 – Day One Biopharmaceuticals was downgraded by JonesTrading from “buy” to “hold”. They now have a $21.50 price target on the stock, up from $20.00.
• 3/6/2026 – Day One Biopharmaceuticals was downgraded by Needham & Company LLC from “buy” to “hold”.
• 2/25/2026 – Day One Biopharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/25/2026 – Day One Biopharmaceuticals had its price target raised by Wedbush from $29.00 to $30.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Day One Biopharmaceuticals had its price target lowered by Needham & Company LLC from $18.00 to $17.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Day One Biopharmaceuticals had its price target lowered by HC Wainwright from $25.00 to $22.00. They now have a “buy” rating on the stock.
• 1/26/2026 – Day One Biopharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity

In other news, insider Lauren Merendino sold 5,814 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $67,442.40. Following the sale, the insider owned 60,157 shares in the company, valued at $697,821.20. This trade represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Adam Dubow sold 6,395 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the transaction, the insider owned 72,694 shares of the company’s stock, valued at $843,250.40. This trade represents a 8.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,461 shares of company stock valued at $422,948 over the last quarter. 6.20% of the stock is owned by insiders.

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.